We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+9.37%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$750M
AUM Growth
+$14.3M
Cap. Flow
+$49M
Cap. Flow %
6.53%
Top 10 Hldgs %
50.53%
Holding
71
New
20
Increased
16
Reduced
11
Closed
15

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$31.4M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$17.5M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15M
4
ROIV icon
Roivant Sciences
ROIV
+$13.6M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$12.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$28.5M
2
ACLX
Arcellx
ACLX
+$15.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$15.8M
4
RCUS icon
Arcus Biosciences
RCUS
+$15.2M
5
IMVT icon
Immunovant
IMVT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 93.46%
2 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
26
BridgeBio Pharma
BBIO
$16.5B
$10.5M 1.41%
400,000
+100,000
+33% +$2.84M
RYTM icon
27
Rhythm Pharmaceuticals
RYTM
$7.28B
$9.17M 1.22%
+400,000
New +$8.96M
KALV
28
DELISTED
KalVista Pharmaceuticals
KALV
$8.67M 1.16%
+900,000
New +$9.2M
VTYX
29
DELISTED
Ventyx Biosciences
VTYX
$7.81M 1.04%
225,000
-25,000
-10% -$864K
CRNX icon
30
Crinetics Pharmaceuticals
CRNX
$8.87B
$7.43M 0.99%
+250,000
New +$5.15M
GRCL
31
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$7.27M 0.97%
2,525,000
+725,000
+40% +$2.65M
CMPS
32
Compass Pathways
CMPS
$1.52B
$7.03M 0.94%
+950,000
New +$8.41M
RVMD icon
33
Revolution Medicines
RVMD
$40B
$6.92M 0.92%
+250,000
New +$7.41M
MOR
34
DELISTED
MorphoSys AG American Depositary Shares
MOR
$6.38M 0.85%
950,000
-250,000
-21% -$1.93M
RPTX
35
CALL
DELISTED
Repare Therapeutics
RPTX
$6.04M 0.81%
+500,000
New +$5.16M
GERN icon
36
Geron
GERN
$949M
$5.83M 0.78%
2,750,000
+550,000
+25% +$1.49M
MRUS
37
DELISTED
Merus
MRUS
$5.78M 0.77%
+245,000
New +$5.94M
ALXO icon
38
ALX Oncology
ALXO
$272M
$4.8M 0.64%
1,000,000
– –
ETNB
39
DELISTED
89bio
ETNB
$4.79M 0.64%
+310,000
New +$5.2M
IOVA icon
40
CALL
Iovance Biotherapeutics
IOVA
$2.19B
$4.55M 0.61%
+1,000,000
New +$6.53M
DCTH icon
41
Delcath Systems
DCTH
$412M
$4.23M 0.56%
1,044,444
-134,343
-11% -$630K
ELVN icon
42
Enliven Therapeutics
ELVN
$3.77B
$4.19M 0.56%
307,076
– –
ATXS
43
DELISTED
Astria Therapeutics
ATXS
$4.07M 0.54%
544,960
– –
SLNO
44
DELISTED
Soleno Therapeutics
SLNO
$3.69M 0.49%
+125,000
New +$757K
RPTX
45
DELISTED
Repare Therapeutics
RPTX
$3.62M 0.48%
+300,000
New +$3.1M
VERV
46
DELISTED
Verve Therapeutics
VERV
$2.85M 0.38%
+215,000
New +$3.46M
ZURA icon
47
Zura Bio
ZURA
$511M
$2.8M 0.37%
+424,000
New +$2.83M
SYRE icon
48
Spyre Therapeutics
SYRE
$8.69B
$2.57M 0.34%
210,000
+84,285
+67% +$1.11M
AMAM
49
DELISTED
Ambrx Biopharma Inc
AMAM
$1.32M 0.18%
+115,000
New +$1.57M
VIGL
50
DELISTED
Vigil Neuroscience
VIGL
$1.02M 0.14%
188,390
– –
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2023 Portfolio in Review

As of Q3 2023, Logos Global Management held 71 positions worth $750M, up 1.9% from $735M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Logos Global Management deployed $49M of net new capital in Q3 2023, opening 20 new positions and adding to 16 existing holdings. Its largest new stake was Cerevel Therapeutics Holdings, Inc. Common Stock: 700,000 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $15.8M trimmed.

  • Logos Global Management's largest Q3 2023 buy was Cerevel Therapeutics Holdings, Inc. Common Stock: 700,000 shares worth $15.3M.
  • Logos Global Management added most to Rocket Pharmaceuticals in Q3 2023, an estimated $31.4M increase.
  • Logos Global Management's biggest Q3 2023 reduction was Neurocrine Biosciences, cutting an estimated $15.8M.
  • Logos Global Management fully exited Biogen in Q3 2023, selling an estimated $28.5M.
  • Logos Global Management's ten largest holdings make up 51% of its $750M portfolio in Q3 2023.
  • Logos Global Management opened 20 new positions and closed 15 in Q3 2023.
  • Logos Global Management's portfolio value rose 1.9% quarter-over-quarter to $750M.

Based on Logos Global Management's 13F filing for Q3 2023, filed 14 Nov 2023.